Kiran Mazumdar-Shaw - 12 Sep 2024 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: BCAX
Reported as of: 12 Sep 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Sep 2024, 16:35:31 UTC
Next SEC filing: 10 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Lara Meisner, Attorney-in-Fact

Key filing fact

Kiran Mazumdar-Shaw filed Form 4 for Bicara Therapeutics Inc. (BCAX) on 16 Sep 2024.

Key facts

This page summarizes Kiran Mazumdar-Shaw's Form 4 filing for Bicara Therapeutics Inc. (BCAX).
9 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 16 Sep 2024, 16:35.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCAX transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +4,327,365
Change %: +3738%
Price: $0.000000
Shares after: 4,443,122
Date: 16 Sep 2024
Ownership: By Biocon Limited
Footnotes: F1, F2

BCAX transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +1,080,775
Change %
Price: $0.000000
Shares after: 1,080,775
Date: 16 Sep 2024
Ownership: By Biocon Pharma Inc.
Footnotes: F1, F3

BCAX transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +324,552
Change %
Price: $0.000000
Shares after: 324,552
Date: 16 Sep 2024
Ownership: By Glentech International
Footnotes: F1, F4

BCAX transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +432,736
Change %
Price: $0.000000
Shares after: 432,736
Date: 16 Sep 2024
Ownership: By Carica Investments
Footnotes: F1, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCAX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +23,746
Change %
Price: $0.000000
Shares after: 23,746
Date: 12 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,746
Exercise price: $18.00
Footnotes: F6

BCAX transaction Derivative

Series Seed Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -40,000,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 16 Sep 2024
Ownership: By Biocon Limited
Underlying class: Common Stock
Underlying amount: 4,327,365
Exercise price
Footnotes: F1, F2

BCAX transaction Derivative

Series Seed Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -9,990,144
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 16 Sep 2024
Ownership: By Biocon Pharma Inc.
Underlying class: Common Stock
Underlying amount: 1,080,775
Exercise price
Footnotes: F1, F3

BCAX transaction Derivative

Series Seed Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -3,000,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 16 Sep 2024
Ownership: By Glentech International
Underlying class: Common Stock
Underlying amount: 324,552
Exercise price
Footnotes: F1, F4

BCAX transaction Derivative

Series Seed Redeemable Convertible Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -4,000,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 16 Sep 2024
Ownership: By Carica Investments
Underlying class: Common Stock
Underlying amount: 432,736
Exercise price
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date.

Footnote F2

Shares held by Biocon Limited ("Biocon Ltd"). The Reporting Person is the managing member of Biocon Ltd and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F3

Shares held by Biocon Pharma Inc. ("Biocon Pharma"). The Reporting Person is the managing member of Biocon Pharma and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F4

Shares held by Glentech International ("Glentech"). The Reporting Person is the managing member of Glentech and disclaims beneficial ownership of such shares for purposes of Section 16 of Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F5

Shares held by Carica Investments ("Carica"). The Reporting Person is the managing partner of Carica and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F6

The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.